Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 8
2011 2
2012 1
2013 1
2014 3
2015 3
2016 2
2017 5
2018 2
2019 3
2020 5
2021 3
2022 6
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Among authors: luetkens t. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
Role of immunotherapy in Ewing sarcoma.
Morales E, Olson M, Iglesias F, Dahiya S, Luetkens T, Atanackovic D. Morales E, et al. Among authors: luetkens t. J Immunother Cancer. 2020 Dec;8(2):e000653. doi: 10.1136/jitc-2020-000653. J Immunother Cancer. 2020. PMID: 33293354 Free PMC article. Review.
Targeting the tumor microenvironment of Ewing sarcoma.
Morales E, Olson M, Iglesias F, Luetkens T, Atanackovic D. Morales E, et al. Among authors: luetkens t. Immunotherapy. 2021 Dec;13(17):1439-1451. doi: 10.2217/imt-2020-0341. Epub 2021 Oct 21. Immunotherapy. 2021. PMID: 34670399 Review.
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Vander Mause ER, et al. Among authors: luetkens t. Sci Transl Med. 2023 Jul 19;15(705):eadd7900. doi: 10.1126/scitranslmed.add7900. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467316
Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D, Luetkens T. Atanackovic D, et al. Among authors: luetkens t. Semin Cancer Biol. 2018 Oct;52(Pt 2):198-206. doi: 10.1016/j.semcancer.2018.05.005. Epub 2018 Jun 18. Semin Cancer Biol. 2018. PMID: 29775689 Review.
Immunotherapies targeting CD38 in Multiple Myeloma.
Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Atanackovic D, et al. Among authors: luetkens t. Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Oncoimmunology. 2016. PMID: 27999737 Free PMC article. Review.
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.
Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. Hendrickson PG, et al. Among authors: luetkens t. Oncoimmunology. 2019 Oct 13;9(1):1673129. doi: 10.1080/2162402X.2019.1673129. eCollection 2020. Oncoimmunology. 2019. PMID: 32002284 Free PMC article. Review.
The role of surface molecule CD229 in Multiple Myeloma.
Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D. Olson M, et al. Among authors: luetkens t. Clin Immunol. 2019 Jul;204:69-73. doi: 10.1016/j.clim.2018.10.006. Epub 2018 Oct 13. Clin Immunol. 2019. PMID: 30326256 Review.
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Among authors: luetkens t. Oncoimmunology. 2017 Mar 28;6(5):e1308618. doi: 10.1080/2162402X.2017.1308618. eCollection 2017. Oncoimmunology. 2017. PMID: 28638731 Free PMC article. Review.
50 results